Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.

Androgen Receptor Antagonists / pharmacology Animals Cell Line, Tumor Chromatin / genetics DNA Methylation / genetics DNA-Binding Proteins / genetics Gene Expression Regulation, Neoplastic / drug effects Gene Knockout Techniques Gonadal Steroid Hormones / genetics Hepatocyte Nuclear Factor 3-alpha / genetics Heterografts Histone Demethylases / genetics Humans Male Mice Prostate / metabolism Prostatic Neoplasms / genetics Protein Binding / genetics Receptors, Androgen / genetics

Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
10 2020
Historique:
received: 01 05 2018
accepted: 24 07 2020
pubmed: 2 9 2020
medline: 25 11 2020
entrez: 2 9 2020
Statut: ppublish

Résumé

FOXA1 functions as a pioneer transcription factor by facilitating the access to chromatin for steroid hormone receptors, such as androgen receptor and estrogen receptor

Identifiants

DOI: 10.1038/s41588-020-0681-7 PMID: 32868907 PMC: PMC7541538
pubmed: 32868907
doi: 10.1038/s41588-020-0681-7
pii: 10.1038/s41588-020-0681-7
pmc: PMC7541538
mid: NIHMS1615048
doi:

Substances chimiques

Androgen Receptor Antagonists 0
Chromatin 0
DNA-Binding Proteins 0
FOXA1 protein, human 0
Gonadal Steroid Hormones 0
Hepatocyte Nuclear Factor 3-alpha 0
Receptors, Androgen 0
Histone Demethylases EC 1.14.11.-
KDM1A protein, human EC 1.5.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1011-1017

Subventions

Organisme : NCI NIH HHS
ID : R01 CA211350
Pays : United States
Organisme : CIHR
ID : 152864
Pays : Canada
Organisme : NCI NIH HHS
ID : U54 CA156732
Pays : United States
Organisme : CIHR
ID : 142246
Pays : Canada
Organisme : NCI NIH HHS
ID : U54 CA156734
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA163227
Pays : United States
Organisme : CIHR
ID : 152863
Pays : Canada
Organisme : NCI NIH HHS
ID : R00 CA166507
Pays : United States
Organisme : NIDDK NIH HHS
ID : U54 DK104310
Pays : United States
Organisme : CIHR
ID : 159567
Pays : Canada

Commentaires et corrections

Type : CommentIn

Références

Gao, N. et al. The role of hepatocyte nuclear factor-3 alpha (forkhead box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 17, 1484–1507 (2003).
doi: 10.1210/me.2003-0020 pubmed: 12750453
Carroll, J. S. et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33–43 (2005).
doi: 10.1016/j.cell.2005.05.008 pubmed: 16009131
Jozwik, K. M. & Carroll, J. S. Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 12, 381–385 (2012).
doi: 10.1038/nrc3263 pubmed: 22555282
Yang, Y. A. & Yu, J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2, 144–151 (2015).
pubmed: 26114156 pmcid: 4477823 doi: 10.1016/j.gendis.2015.01.003
Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).
doi: 10.1016/j.cell.2004.12.012 pubmed: 15620353
Shi, Y. J. et al. Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell 19, 857–864 (2005).
doi: 10.1016/j.molcel.2005.08.027 pubmed: 16140033
Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436–439 (2005).
doi: 10.1038/nature04020 pubmed: 16079795
Wissmann, M. et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 9, 347–353 (2007).
doi: 10.1038/ncb1546 pubmed: 17277772
Metzger, E. et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat. Cell Biol. 10, 53–60 (2008).
doi: 10.1038/ncb1668 pubmed: 18066052
Metzger, E. et al. Phosphorylation of histone H3T6 by PKCβ
doi: 10.1038/nature08839 pubmed: 20228790
Cai, C. et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 9, 1618–1627 (2014).
pubmed: 25482560 pmcid: 4268354 doi: 10.1016/j.celrep.2014.11.008
Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958–970 (2008).
pubmed: 18358809 pmcid: 2323438 doi: 10.1016/j.cell.2008.01.018
Swinstead, E. E. et al. Steroid receptors reprogram FoxA1 occupancy through dynamic chromatin transitions. Cell 165, 593–605 (2016).
pubmed: 27062924 pmcid: 4842147 doi: 10.1016/j.cell.2016.02.067
Metzger, E. et al. Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation. Nat. Struct. Mol. Biol. 23, 132–139 (2016).
doi: 10.1038/nsmb.3153 pubmed: 26751641
Sehrawat, A. et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc. Natl Acad. Sci. USA 115, E4179–E4188 (2018).
doi: 10.1073/pnas.1719168115 pubmed: 29581250 pmcid: 5939079
Mimasu, S. et al. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 49, 6494–6503 (2010).
doi: 10.1021/bi100299r pubmed: 20568732
Mohammad, H. P. et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 28, 57–69 (2015).
doi: 10.1016/j.ccell.2015.06.002 pubmed: 26175415
He, H. H. et al. Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res. 22, 1015–1025 (2012).
pubmed: 22508765 pmcid: 3371710 doi: 10.1101/gr.133280.111
Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390–394 (2011).
pubmed: 21572438 pmcid: 3117022 doi: 10.1038/nature10006
Jin, H. J., Zhao, J. C., Wu, L., Kim, J. & Yu, J. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat. Commun. 5, 3972 (2014).
pubmed: 24875621 doi: 10.1038/ncomms4972
Sheng, W. et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell 174, 549–563.e19 (2018).
pubmed: 29937226 pmcid: 6063761 doi: 10.1016/j.cell.2018.05.052
Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).
pubmed: 25184630 pmcid: 4201502 doi: 10.1056/NEJMoa1315815
Yu, Z. et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin. Cancer Res. 20, 1590–1600 (2014).
pubmed: 24449822 pmcid: 4022291 doi: 10.1158/1078-0432.CCR-13-1863
Sharp, A. et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J. Clin. Invest. 129, 192–208 (2019).
doi: 10.1172/JCI122819 pubmed: 30334814
Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16–22 (2009).
pubmed: 19117982 pmcid: 2614301 doi: 10.1158/0008-5472.CAN-08-2764
Li, Y. et al. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 71, 2108–2117 (2011).
pubmed: 21248069 pmcid: 3059379 doi: 10.1158/0008-5472.CAN-10-1998
Huang, J. et al. p53 is regulated by the lysine demethylase LSD1. Nature 449, 105–108 (2007).
doi: 10.1038/nature06092 pubmed: 17805299
Wang, J. et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41, 125–129 (2009).
doi: 10.1038/ng.268 pubmed: 19098913
Kontaki, H. & Talianidis, I. Lysine methylation regulates E2F1-induced cell death. Mol. Cell 39, 152–160 (2010).
doi: 10.1016/j.molcel.2010.06.006 pubmed: 20603083
Jozwik, K. M., Chernukhin, I., Serandour, A. A., Nagarajan, S. & Carroll, J. S. FOXA1 directs H3K4 monomethylation at enhancers via recruitment of the methyltransferase MLL3. Cell Rep. 17, 2715–2723 (2016).
pubmed: 27926873 pmcid: 5177601 doi: 10.1016/j.celrep.2016.11.028
Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685–689 (2012).
pubmed: 22610119 pmcid: 3673022 doi: 10.1038/ng.2279
Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).
pubmed: 22722839 pmcid: 3396711 doi: 10.1038/nature11125
Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).
doi: 10.1016/j.cell.2015.10.025
Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).
pubmed: 26000489 pmcid: 4484602 doi: 10.1016/j.cell.2015.05.001
Parolia, A. et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 571, 413–418 (2019).
pubmed: 31243372 pmcid: 6661908 doi: 10.1038/s41586-019-1347-4
Li, J. et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580, 93–99 (2020).
pubmed: 32238934 doi: 10.1038/s41586-020-2135-x
Iwafuchi, M. et al. Gene network transitions in embryos depend upon interactions between a pioneer transcription factor and core histones. Nat. Genet. 52, 418–427 (2020).
doi: 10.1038/s41588-020-0591-8 pubmed: 32203463 pmcid: 7901023
Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
doi: 10.1056/NEJMoa1207506 pubmed: 22894553
Park, J. W., Lee, J. K., Witte, O. N. & Huang, J. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod. Pathol. 30, 1262–1272 (2017).
pubmed: 28621319 pmcid: 6330177 doi: 10.1038/modpathol.2017.44
Brechka, H., Bhanvadia, R. R., VanOpstall, C. & Vander Griend, D. J. HOXB13 mutations and binding partners in prostate development and cancer: function, clinical significance, and future directions. Genes Dis. 4, 75–87 (2017).
pubmed: 28798948 pmcid: 5548135 doi: 10.1016/j.gendis.2017.01.003
Maes, T. et al. ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell 33, 495–511.e12 (2018).
doi: 10.1016/j.ccell.2018.02.002 pubmed: 29502954
Pishas, K. I. et al. Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP-2509 engages the endoplasmic reticulum stress response. Mol. Cancer Ther. 17, 1902–1916 (2018).
pubmed: 29997151 pmcid: 6201274 doi: 10.1158/1535-7163.MCT-18-0373
Corey, E. et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 55, 239–246 (2003).
doi: 10.1002/pros.10198 pubmed: 12712403
Nguyen, H. M. et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate 77, 654–671 (2017).
pubmed: 28156002 pmcid: 5354949 doi: 10.1002/pros.23313
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
pubmed: 21612468 pmcid: 3471149 doi: 10.1056/NEJMoa1014618
Wang, Q. et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245–256 (2009).
pubmed: 19632176 pmcid: 2726827 doi: 10.1016/j.cell.2009.04.056
Corces, M. R. et al. An improved ATAC–seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959–962 (2017).
pubmed: 28846090 pmcid: 5623106 doi: 10.1038/nmeth.4396
Li, H. Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly. Bioinformatics 28, 1838–1844 (2012).
pubmed: 22569178 pmcid: 3389770 doi: 10.1093/bioinformatics/bts280
Hsi-Yang Fritz, M., Leinonen, R., Cochrane, G. & Birney, E. Efficient storage of high throughput DNA sequencing data using reference-based compression. Genome Res. 21, 734–740 (2011).
pubmed: 21245279 pmcid: 3083090 doi: 10.1101/gr.114819.110
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Zhu, L. J. et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics 11, 237 (2010).
pubmed: 20459804 pmcid: 3098059 doi: 10.1186/1471-2105-11-237
Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
pubmed: 27079975 pmcid: 4987876 doi: 10.1093/nar/gkw257
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
doi: 10.1093/bioinformatics/bts635 pubmed: 23104886
Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184–2185 (2012).
doi: 10.1093/bioinformatics/bts356 pubmed: 22743226
Wang, S. et al. Target analysis by integration of transcriptome and ChIP–seq data with BETA. Nat. Protoc. 8, 2502–2515 (2013).
pubmed: 24263090 pmcid: 4135175 doi: 10.1038/nprot.2013.150
Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27–33 (2011).
doi: 10.1038/ng.730 pubmed: 21151129
Zhang, Y. et al. Nucleation of DNA repair factors by FOXA1 links DNA demethylation to transcriptional pioneering. Nat. Genet. 48, 1003–1013 (2016).
doi: 10.1038/ng.3635 pubmed: 27500525

Auteurs

Shuai Gao (S)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
ORCID: 0000-0002-7304-8801

Sujun Chen (S)

Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada.

Dong Han (D)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

Zifeng Wang (Z)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

Muqing Li (M)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

Wanting Han (W)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
ORCID: 0000-0002-2173-3647

Anna Besschetnova (A)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

Mingyu Liu (M)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

Feng Zhou (F)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

David Barrett (D)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

My Phu Luong (MP)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

Jude Owiredu (J)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

Yi Liang (Y)

Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada.

Musaddeque Ahmed (M)

Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada.

Jessica Petricca (J)

Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada.

Susan Patalano (S)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

Jill A Macoska (JA)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.

Eva Corey (E)

Department of Urology, University of Washington, Seattle, WA, USA.
ORCID: 0000-0002-9244-3807

Sen Chen (S)

Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

Steven P Balk (SP)

Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. sbalk@bidmc.harvard.edu.
ORCID: 0000-0002-4546-7371

Housheng Hansen He (HH)

Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. hansenhe@uhnresearch.ca.
Princess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada. hansenhe@uhnresearch.ca.
ORCID: 0000-0003-2898-3363

Changmeng Cai (C)

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA. changmeng.cai@umb.edu.
ORCID: 0000-0002-8701-2586

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Antagonistes des androgènes › Antagonistes du récepteur des androgènes › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Eucaryotes › Animaux › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Structures de chromosome › Chromatine › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Phénomènes génétiques › Méthylation de l'ADN › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de liaison à l'ADN › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Ciblage de gène › Techniques de knock-out de gènes › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif hélice ailée › Facteurs de transcription Forkhead › Facteur nucléaire hépatocytaire HNF-3 alpha › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Régions du corps › Transplants › Hétérogreffes › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxidoreductases acting on CH-NH group donors › Oxidoreductases, (N-demethylating) › Histone Demethylases › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Tissus › Glandes exocrines › Prostate › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Chromatin binding of FOXA1 is promoted by...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs aux androgènes › Chromatin binding of FOXA1 is promoted by...